Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 68.2% from a year ago
Accumulated OCI stood at $14K at the end of Q1 FY2026, down 68.2% from a year earlier and down 82.7% from the prior quarter.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -68.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 81K USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 Accumulated OCI of $14K is the highest of the 11 companies compared; the peer median is -$57K.
- Its year-over-year change of -68.2% is the 4th highest of 9, against a peer median of -106.9%.
- Accumulated OCI amounts to 0.0% of total assets for AARD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14K | -68.2% | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | -$6K | — | — | 0.0% | |
| Mar 2026 | -$23K | -113.8% | — | 0.0% | |
| Mar 2026 | -$91K | -148.1% | — | 0.1% | |
| Mar 2026 | -$133K | -1050.0% | — | 0.1% | |
| Mar 2026 | -$368K | -45.5% | — | 0.2% | |
| Mar 2026 | -$734K | -227.7% | — | 0.2% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | -$4.5M | -9.1% | — | 3.1% |
| Peer median (excluding AARD) | -$57K | -106.9% | — | 0.0% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.